FourThought Financial’s Trillium Therapeutics Inc. TRIL Stock Holding History

FourThought Financial’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,267	Closed	-$39K	–	1616
2021 Q3	$39K	Buy	2,267 +35	+2%	+$409	0.01%	766
2021 Q2	$21K	Sell	2,232 -31	-1%	-$292	﹤0.01%	938
2021 Q1	$24K	Sell	2,263 -265	-10%	-$3.28K	﹤0.01%	867
2020 Q4	$37K	Buy	+2,528	New	+$36.5K	0.01%	739

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

FourThought Financial's TRIL Position: Q4 2021 in Review

FourThought Financial sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 2,267 shares — an estimated $39K sold.

FourThought Financial first reported a position in TRIL in Q4 2020 and held it in 4 quarters. The position peaked at $39K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

FourThought Financial reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
FourThought Financial sold 2,267 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $39K.
FourThought Financial first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 4 quarters.
FourThought Financial's Trillium Therapeutics Inc. position peaked at $39K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on FourThought Financial's 13F filing for Q4 2021, filed 14 Jan 2022.